Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology
Isarna Therapeutics, a leader in TGF-ß targeted antisense therapeutics, has submitted a Clinical Trial Authorization (CTA) application with the German Regulatory Authority to begin human studies on its lead program ISTH0036, a selective TGF-ß2 antisense oligonucleotide. TGF-ß2 is considered a prime disease driver in major ophthalmic diseases such as glaucoma, secondary cataract, and proliferative vitreoretinopathy.
“Glaucoma is the leading cause of irreversible blindness worldwide. By targeting TGF-ß2 we believe that ISTH0036 represents an important innovative and so far unexplored new approach to stopping and potentially modifying the course of the disease in its advanced stages and, therefore, it addresses a high unmet medical need,” stated Dr Philippe Calais, CEO of Isarna. “We expect to begin studies in the first half of 2015 and are seeking funding to advance this as well as our lead TGF-ß isoform specific programmes in fibrosis and oncology through the proof-of-concept stage.”
Dr Calais continued: “Isarna made significant progress during the course of 2014, as it was only a year ago that we announced our agreement with Santaris providing us with exclusive access to their LNA chemistry technology, and today we announce our first CTA filing for a major disease in ophthalmology.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance